- Home
- MPB vs PLRX Comparison
MPB vs PLRX Comparison
Compare MPB & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPB
- PLRX
- Stock Information
- Founded
- MPB 1868
- PLRX 2015
- Country
- MPB United States
- PLRX United States
- Employees
- MPB N/A
- PLRX N/A
- Industry
- MPB Major Banks
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- MPB Finance
- PLRX Health Care
- Exchange
- MPB Nasdaq
- PLRX Nasdaq
- Market Cap
- MPB 525.0M
- PLRX 680.3M
- IPO Year
- MPB N/A
- PLRX 2020
- Fundamental
- Price
- MPB $29.19
- PLRX $11.37
- Analyst Decision
- MPB Buy
- PLRX Strong Buy
- Analyst Count
- MPB 2
- PLRX 7
- Target Price
- MPB $36.00
- PLRX $40.50
- AVG Volume (30 Days)
- MPB 71.0K
- PLRX 485.5K
- Earning Date
- MPB 01-22-2025
- PLRX 02-26-2025
- Dividend Yield
- MPB 2.74%
- PLRX N/A
- EPS Growth
- MPB 14.41
- PLRX N/A
- EPS
- MPB 2.91
- PLRX N/A
- Revenue
- MPB $173,416,000.00
- PLRX N/A
- Revenue This Year
- MPB N/A
- PLRX N/A
- Revenue Next Year
- MPB $19.26
- PLRX N/A
- P/E Ratio
- MPB $10.05
- PLRX N/A
- Revenue Growth
- MPB 4.93
- PLRX N/A
- 52 Week Low
- MPB $19.20
- PLRX $10.22
- 52 Week High
- MPB $33.87
- PLRX $18.00
- Technical
- Relative Strength Index (RSI)
- MPB 46.67
- PLRX 44.60
- Support Level
- MPB $30.02
- PLRX $10.35
- Resistance Level
- MPB $31.36
- PLRX $11.07
- Average True Range (ATR)
- MPB 0.75
- PLRX 0.61
- MACD
- MPB 0.16
- PLRX 0.06
- Stochastic Oscillator
- MPB 45.23
- PLRX 43.50
About MPB Mid Penn Bancorp
Mid Penn Bancorp Inc operates in the financial services domain. It conducts commercial banking and trust business in the United States. Its range of services comprises mortgage and home equity loans, secured and unsecured consists and consumer loans, lines of credit, construction financing, farm loans, community development, local government loans, and various types of time and demand deposits.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.